Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.01% is 78% above its 5-year average of -174.45%, near the high end of its 5-year range (-409.38%–-38.01%).
84.91% above its 12-month average of -251.96%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.68%.
RETURN ON ASSETS (ROA)
-38.01%
RETURN ON ASSETS (ROA) AVG TTM
-251.96%
RETURN ON ASSETS (ROA) AVG 3Y
-211.47%
RETURN ON ASSETS (ROA) AVG 5Y
-174.45%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+84.91%
CURRENT VS 3Y AVG
+82.03%
CURRENT VS 5Y AVG
+78.21%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-23.27%
median of 386 covered companies
CURRENT VS SECTOR MEDIAN
-63.31%
vs the sector median at left
Anteris Technologies Global Corp.
Market Cap
$734.10M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
Market Cap
$719.64M
Return on Assets (ROA)
-59.88%
TTM Avg
-116.93%
3Y Avg
-132.27%
5Y Avg
-105.87%
Market Cap
$749.55M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$709.33M
Return on Assets (ROA)
2.24%
TTM Avg
3.98%
3Y Avg
2.51%
5Y Avg
4.09%
Market Cap
$767.46M
Return on Assets (ROA)
-20.44%
TTM Avg
-45.26%
3Y Avg
-91.41%
5Y Avg
-102.66%
Market Cap
$698.60M
Return on Assets (ROA)
-103.29%
TTM Avg
-79.28%
3Y Avg
-61.36%
5Y Avg
-60.54%
Market Cap
$774.32M
Return on Assets (ROA)
-36.55%
TTM Avg
-44.22%
3Y Avg
-44.22%
5Y Avg
-44.22%
Market Cap
$775.72M
Return on Assets (ROA)
-32.91%
TTM Avg
-25.26%
3Y Avg
-23.04%
5Y Avg
-20.66%
Market Cap
$776.24M
Return on Assets (ROA)
-13.47%
TTM Avg
-22.22%
3Y Avg
-41.40%
5Y Avg
-40.82%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $734.10M | -38.01% | -251.96% | -211.47% | -174.45% |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | -59.88% | -116.93% | -132.27% | -105.87% |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | -42.53% | -41.06% | -49.54% | -47.47% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $709.33M | 2.24% | 3.98% | 2.51% | 4.09% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $767.46M | -20.44% | -45.26% | -91.41% | -102.66% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | -103.29% | -79.28% | -61.36% | -60.54% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | -36.55% | -44.22% | -44.22% | -44.22% |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | -32.91% | -25.26% | -23.04% | -20.66% |
| Geron Corporation (GERN)vs › | $776.24M | -13.47% | -22.22% | -41.40% | -40.82% |
| Annexon, Inc. (ANNX)vs › | $688.14M | -82.36% | -56.97% | -52.21% | -45.34% |
ROA
-38.0%
ROE
-41.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -409.38% |
| 2024-12-31 | -94.54% |
| 2023-12-31 | -150.76% |
| 2022-12-31 | -191.20% |
| 2021-12-31 | -80.11% |
| 2020-12-31 | -120.73% |
